SG11202012014UA - Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof - Google Patents

Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

Info

Publication number
SG11202012014UA
SG11202012014UA SG11202012014UA SG11202012014UA SG11202012014UA SG 11202012014U A SG11202012014U A SG 11202012014UA SG 11202012014U A SG11202012014U A SG 11202012014UA SG 11202012014U A SG11202012014U A SG 11202012014UA SG 11202012014U A SG11202012014U A SG 11202012014UA
Authority
SG
Singapore
Prior art keywords
immunoconjugates
antibodies
antibody fragments
fragments
antibody
Prior art date
Application number
SG11202012014UA
Inventor
Jay M Short
Gerhard Frey
Hwai Wen Chang
William Boyle
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of SG11202012014UA publication Critical patent/SG11202012014UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202012014UA 2018-06-05 2019-06-04 Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof SG11202012014UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680698P 2018-06-05 2018-06-05
US201862752567P 2018-10-30 2018-10-30
PCT/US2019/035395 WO2019236585A1 (en) 2018-06-05 2019-06-04 Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11202012014UA true SG11202012014UA (en) 2021-01-28

Family

ID=68769207

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012014UA SG11202012014UA (en) 2018-06-05 2019-06-04 Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

Country Status (12)

Country Link
US (2) US11834472B2 (en)
EP (1) EP3802596A4 (en)
JP (2) JP7473977B2 (en)
KR (1) KR20210019464A (en)
CN (1) CN112292396A (en)
AU (1) AU2019282626A1 (en)
CA (1) CA3102391A1 (en)
IL (1) IL279086A (en)
MX (1) MX2020013243A (en)
SG (1) SG11202012014UA (en)
TW (1) TW202000697A (en)
WO (1) WO2019236585A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP2005510451A (en) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー Compositions and methods for treating inflammatory disorders
EP1546358A4 (en) * 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif antibodies and methods of using in inflammation
KR20060022289A (en) 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 Antibodies against interleukin-22 and uses therefor
BRPI0516975A (en) 2004-10-22 2008-09-30 Zymogenetics Inc antibody or antigen-binding fragment thereof, pharmaceutical composition, immunoconjugate, hybridoma, monoclonal antibody, and use of an antibody or antigen-binding fragment thereof
CN100515491C (en) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 Medical use of interleukin-22
NZ621483A (en) * 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
AU2013200914B2 (en) * 2005-12-02 2016-01-14 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP2658970B1 (en) 2010-12-31 2016-09-28 Bioatla LLC Express humanization of antibodies
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
DK2970422T3 (en) 2013-03-15 2018-07-16 Hoffmann La Roche IL-22 POLYPEPTIDES AND IL-22 FC-FUSION PROTEINS AND METHODS OF USE
CN107580603A (en) 2015-02-24 2018-01-12 生物蛋白有限公司 Condition active biological protein
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
CA3102391A1 (en) 2019-12-12
IL279086A (en) 2021-01-31
JP7473977B2 (en) 2024-04-24
KR20210019464A (en) 2021-02-22
JP2021527122A (en) 2021-10-11
TW202000697A (en) 2020-01-01
CN112292396A (en) 2021-01-29
US11834472B2 (en) 2023-12-05
US20210230263A1 (en) 2021-07-29
JP2024059724A (en) 2024-05-01
EP3802596A4 (en) 2022-07-20
US20240141035A1 (en) 2024-05-02
WO2019236585A1 (en) 2019-12-12
AU2019282626A1 (en) 2021-01-07
MX2020013243A (en) 2021-05-12
EP3802596A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
IL279015A (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
IL278924A (en) Antibodies specific for gucy2c and uses thereof
IL262173B (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
EP3470427A4 (en) Anti-human interleukin-17a monoclonal antibody, and preparation method and use thereof
EP3753951A4 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
EP3882268A4 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
IL262404A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL291049A (en) Anti-cd47 monoclonal antibody and use thereof
IL277296A (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
EP3672635A4 (en) Monoclonal antibodies against pathological alpha-synuclein, and methods using same
EP3847192A4 (en) Monoclonal antibodies against endotrophin and the use thereof
IL288753A (en) Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11202011232VA (en) Anti-cd63 antibodies, conjugates, and uses thereof
IL283881A (en) Anti-il-17a antibody and use thereof
IL279086A (en) Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3712270A4 (en) Monoclonal antibody and use thereof
SG11202102514QA (en) Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof